APA (7th ed.) Citation

Brown, D., & Gründer, G. (2019). Evaluation of the efficacy, safety, and tolerability of BI 409306, a novel phosphodiesterase 9 inhibitor, in cognitive impairment in schizophrenia: A randomized, double-blind, placebo-controlled, phase II trial. Schizophrenia bulletin, 45(2), . https://doi.org/10.1093/schbul/sby049

Chicago Style (17th ed.) Citation

Brown, David, and Gerhard Gründer. "Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-blind, Placebo-controlled, Phase II Trial." Schizophrenia Bulletin 45, no. 2 (2019). https://doi.org/10.1093/schbul/sby049.

MLA (9th ed.) Citation

Brown, David, and Gerhard Gründer. "Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-blind, Placebo-controlled, Phase II Trial." Schizophrenia Bulletin, vol. 45, no. 2, 2019, https://doi.org/10.1093/schbul/sby049.